In Vitro Fertilization Articles & Analysis
6 news found
Patients with POI usually only have a 5% to 10% chance of spontaneous pregnancy and must rely on donor eggs for conception via in vitro fertilization therapy. The company plans to submit a manuscript for publication in a peer reviewed journal and present the data at future fertility medicine conferences. ...
“For more than 20 years, current approaches to infertility treatment have been limited during the initial stage of therapeutic care, but with the advancement of FemaSeed, we believe a next generation intrauterine procedure may have the opportunity to truly change this traditional paradigm,” said Michael Glassner, MD, Founding Partner and Medical Director of Main Line ...
Osel, Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, today announced that it has entered into a definitive agreement with a consortia comprising Aarhus University, Skive Hospital and Statens Serum Institut of Denmark, and obtained the exclusive worldwide license to inventions resulting from an investigator-initiated ...
Lee, founder and executive chairman of Osel, added, “We currently have ongoing LACTIN-V clinical studies for in vitro fertilization (IVF) and preterm ...
DxNow is developing novel devices for use in assisted reproductive technology (ART) procedures conducted by fertility clinics and OB/GYN practices. The ZyMot devices are intended for preparing motile sperm from semen for use in the treatment of infertile couples by intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), and in vitro ...
The product is intended for ultrasound-guided transfer of embryos into the uterine cavity following in vitro fertilization. The embryo transfer procedure is the last step in the IVF process and critically important to the success of the procedure. ...